Sigilon Therapeutics Reports First Quarter 2022 Financial Results And Business Highlights
On track to announce results from preclinical studies of SIG-005 in second half of 2022
Current cash position expected to fund operating plans into 2024
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the first quarter ended March 31, 2022 as well as certain other business highlights.
“This quarter, we continued to make headway with our strategic reprioritization plans. Due to our strengthened leadership team, we have advanced our clinical and corporate strategy, with a focus on the three strategic areas we previously outlined: MPS-1, diabetes and platform optimization,” said Rogerio Vivaldi, M.D., President and CEO of Sigilon. “To that end, the Sigilon team has been hard at work completing preclinical studies necessary to advance the clinical development of the SIG-005 program in patients with MPS-1, a lysosomal disease. We believe we remain on track to announce the results from our preclinical work in the second half of this year.”
Recent Program Highlights and Anticipated Milestones
About Sigilon Therapeutics
Sigilon Therapeutics, Inc.
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
SOURCE: Sigilon Therapeutics, Inc.